Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dimethyl fumarate - Biogen

Next Previous
Drug Profile

Dimethyl fumarate - Biogen

Alternative Names: BG-00012; BG-12; BG-12 oral fumarate; Delayed-release dimethyl fumarate; Delayed-release DMF; FAG-201; Gastro-resistant dimethyl fumarate; Gastro-resistant DMF; Panaclar; Tecfidera

Latest Information Update: 08 Dec 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec
  • Developer Biogen; Biogen Idec
  • Class Anti-inflammatories; Antihypertensives; Antipsoriatics; Antirheumatics; Cardiovascular therapies; Cytoprotectives; Esters; Fumarates; Small molecules
  • Mechanism of Action NF-E2-related factor 2 stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Phase II Psoriasis
  • No development reported Pulmonary arterial hypertension; Rheumatoid arthritis

Most Recent Events

  • 06 Dec 2022 The Enlarged Board of Appeal (the EBA) of the European Patent Office dismisses decision of the Technical Board of Appeal of the EPO Opposition Division to revoke the EP2801355 patent
  • 21 Jul 2022 Biogen terminates a phase III in Multiple sclerosis (In children's, In adolescents, Combination therapy) in Colombia, Jordan, South Korea, Malaysia, Mexico, Saudi Arabia, Taiwan, Thailand, Tunisia, Turkey, Estonia, Hungary and USA (SC, Injection) due to long-term difficulties in fulfilling enrolment commitments(NCT03870763)
  • 21 Jun 2022 Biogen has patent protection related to dimethyl fumarate for treatment of multiple sclerosis in European Union

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top